PCSK9 inhibitors (PCSK9-i) act reducing LDL-c and previous trials showed that they are able to reduce ASCVD (Murphy et al., 2019; Steffens et al., 2020); thus, PCSK9-i treatment is currently a useful lipid-lowering option in FH subjects (Stein et al., 2012). Here, PCSK9 is linked to familial hyperaldosteronism.